welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
recruiting

A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT03769116

condition: Muscular Dystrophy, Duchenne

status: recruiting

purpose:

The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer in DMD patients by measuring biological and clinical endpoints in two parts: a 48-week randomized, double-blinded, placebo-controlled period (Part 1), and a 96-week, double-blinded extension period (Part 2).

intervention: SRP-9001, Placebo

mechanism of action: Gene therapy to introduce a version of dystrophin

results: https://clinicaltrials.gov/ct2/show/results/NCT03769116

last updated: October 21, 2019

study details

start date: December 22, 2018

estimated completion: July 25, 2022

phase of development: Phase 2

size / enrollment: 40

primary outcomes:

  • Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 144 weeks ]
  • Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 144 weeks ]
  • Incidence of Adverse Events of Special Interest (AESIs) [ Time Frame: Up to 144 weeks ]
  • Change From Baseline in Quantity of Microdystrophin Protein Expression Measured by Western Blot [ Time Frame: Baseline up to Week 12 ]

secondary outcomes:

  • Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score [ Time Frame: Baseline up to Week 48 ]
  • Change From Baseline in Time to Rise From the Floor and Ascend 4 Steps [ Time Frame: Baseline up to Week 48 ]
  • Change From Baseline in Time of 10 Meter and 100 Meter Timed Test [ Time Frame: Baseline up to Week 48 ]

inclusion criteria:

• Eligible Sexes: all

• Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD phenotype.
• Indication of symptomatic muscular dystrophy by protocol-specified criteria.
• Ability to cooperate with motor assessment testing.
• Stable dose equivalent of oral corticosteroids for at least 12 weeks.

exclusion criteria:
• Impaired cardiovascular function on ECHO.
• Prior or ongoing medical condition on physical examination, ECG, or laboratory findings that could adversely affect subject safety, compromise completion of follow-up, or impair assessment of study results.
• Exposure to another investigational drug or exon skipping medication within months.
• Exposure to an investigational or commercial gene therapy product.
• Abnormal liver or renal function by protocol-specified criteria

study contacts

sponsor: Sarepta Therapeutics

contacts: Medical Information, +1-888-727-3782, Clinicaltrials@sarepta.com

investigators: Medical Director; Sarepta Therapeutics, Inc.

trial center locations: United States